Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927547 | 0.93 | LRRK2 (0.47) | LRRK2ALDH1A1LMNAMAPK1 | |
| SCHEMBL3993208 | 0.92 | KIFC1 (0.45) | LRRK2ALDH1A1LMNAMAPK1KCNQ3 | |
| SCHEMBL5926518 | 0.92 | LRRK2 (0.47) | LRRK2ALDH1A1LMNAMAPK1 | |
| SCHEMBL5926827 | 0.92 | LRRK2 (0.47) | LRRK2ALDH1A1LMNAMAPK1KIFC1 | |
| SCHEMBL5927061 | 0.92 | LRRK2 (0.50) | LRRK2ALDH1A1LMNAMAPK1 | |
| SCHEMBL5927429 | 0.92 | LRRK2 (0.47) | LRRK2ALDH1A1LMNAMAPK1CYP26A1 | |
| SCHEMBL5927121 | 0.90 | RXRA (0.46) | LRRK2ALDH1A1LMNAMAPK1KMT2A | |
| SCHEMBL5926948 | 0.90 | LRRK2 (0.46) | LRRK2ALDH1A1LMNAMAPK1CYP26A1 | |
| SCHEMBL5926981 | 0.89 | PTGS2 (0.46) | LRRK2ALDH1A1LMNAMAPK1KCNQ3 | |
| SCHEMBL5926635 | 0.89 | MMP12 (0.49) | LRRK2ALDH1A1LMNAMAPK1KIFC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | LRRK2 638/4885ALDH1A1 2142/4885LMNA 178/4885 |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | LRRK2 1752/4885ALDH1A1 2886/4885LMNA 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.